LP
OPTN

LMR Partners’s OptiNose OPTN Stock Holding History

LMR Partners’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,388
Closed -$40.2K – 1049
2023
Q1 		$40.2K Buy
+1,388
New +$37K ﹤0.01% 978
2021
Q3 		– Sell
-698
Closed -$33K – 1143
2021
Q2 		$33K Buy
+698
New +$35.6K ﹤0.01% 1036

Other funds holding OPTN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LMR Partners's OPTN Position: Q2 2023 in Review

LMR Partners sold out of OptiNose (OPTN) in Q2 2023, closing a stake of 1,388 shares — an estimated $40.2K sold.

LMR Partners first reported a position in OPTN in Q2 2021 and held it in 2 quarters. The position peaked at $40.2K in Q1 2023. 61 funds tracked by Wall St. Rank hold OPTN as of Q2 2023.

  • LMR Partners reported no remaining OptiNose position as of Q2 2023 after selling out during the quarter.
  • LMR Partners sold 1,388 OptiNose shares in Q2 2023, an estimated $40.2K.
  • LMR Partners first reported a position in OptiNose in Q2 2021 and held it in 2 quarters.
  • LMR Partners's OptiNose position peaked at $40.2K in Q1 2023.
  • 61 funds tracked by Wall St. Rank held OptiNose as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.